BioTech Social Media and Updates

Peptides Shift From Biomarkers to Feeling Control, Raising Risks
SocialMar 30, 2026

Peptides Shift From Biomarkers to Feeling Control, Raising Risks

I think peptides are popular because they give people a feeling of power and control. One feels helpless when they can't sleep, stop scrolling, eat well or exercise consistently. A few injections wrestles back a feeling of control. Evidence...

By Bryan Johnson
Setidegrasib’s KRAS Degradation Still Unproven in Cancer
SocialMar 30, 2026

Setidegrasib’s KRAS Degradation Still Unproven in Cancer

Elegant in theory, unproven in practice: setidegrasib and the case (or not) for KRAS degradation in NSCLC and pancreatic cancer: https://t.co/NuaOJ2amgn https://t.co/i9FpK4W19W

By Sally Church
Lilly‑InsilicoMeds Partnership Grows to $2.75 B
SocialMar 30, 2026

Lilly‑InsilicoMeds Partnership Grows to $2.75 B

30March: How did @EliLillyandCo and @InSilicoMeds begin and expand their collaboration into the up-to-$2.75B partnership announced Sunday? Read about $LLY and $3696 in the latest for @GENbio from me and colleague @xiaofei_lin: https://t.co/KtXOWFjGdq

By Alex Philippidis
LQDA's Superior Delivery Threatens UTHR's Orphan Edge
SocialMar 30, 2026

LQDA's Superior Delivery Threatens UTHR's Orphan Edge

The $UTHR news today is great for IPF patients. But it is also very good news for $LQDA given they have better delivery of the same drug. UTHR has 7-year orphan protection in IPF, but that can be overcome by...

By Peter Suzman
Your Trial Recruitment Fails at the Website Front Door
SocialMar 30, 2026

Your Trial Recruitment Fails at the Website Front Door

Everyone complains that clinical trial recruitment is hard. Fair. 📍 But here is a question not enough people ask: Have you looked closely at your 𝘁𝗿𝗶𝗮𝗹 𝗿𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝘀𝗶𝘁𝗲? I ran one through https://t.co/f9IW600hsB. The science was solid. The 𝗺𝗲𝘀𝘀𝗮𝗴𝗶𝗻𝗴 𝘄𝗮𝘀 𝗻𝗼𝘁. 📉 That is the disconnect. Too...

By Tatyana Kanzaveli
Key FDA Decisions Shaping Biotech Q2 2026
SocialMar 30, 2026

Key FDA Decisions Shaping Biotech Q2 2026

New: 5 FDA decisions to watch in the second quarter of 2026 https://t.co/AVvu8i9kgh $REPL $LLY $AXSM $PFE $ARVN $IONS $ARWR #biotech

By Ben Fidler
R3 Bio's Push for Brainless Human Clones Sparks Ethical Debate
SocialMar 30, 2026

R3 Bio's Push for Brainless Human Clones Sparks Ethical Debate

Here's our story about R3 Bio and the entrepreneur dreaming of brainless human clones. https://t.co/ZJpdffTKNP

By Antonio Regalado
IMMX Completes NEXICART‑2 Enrollment, Paving Path
SocialMar 30, 2026

IMMX Completes NEXICART‑2 Enrollment, Paving Path

$IMMX hits a big milestone: NEXICART-2 enrollment complete BLA-enabling Strong prior efficacy (~75% CR) No approved therapies in R/R AL https://t.co/0iUBMaSetC

By BowTiedBiotech
Senescent Endothelial Cells Direct Plaque Communication Network
SocialMar 30, 2026

Senescent Endothelial Cells Direct Plaque Communication Network

Senescent endothelial cells: key commanders of the cellular communication network within atherosclerotic plaques https://t.co/yzyxR0KPAL https://t.co/RBqSrKkvks

By David Barzilai, MD PhD
Epigenetic Disruption, Not DNA Damage, Drives Accelerated Aging
SocialMar 30, 2026

Epigenetic Disruption, Not DNA Damage, Drives Accelerated Aging

As a medical school professor, I taught that aging was caused by DNA mutations accumulating over time. A landmark study from my friend Dave Sinclair's team in Cell just overturned that entire framework. The researchers created mice that age faster --...

By Robert Lufkin, MD
Gates Foundation Funds TesseraTx's Gene‑editing HIV Cure Research
SocialMar 30, 2026

Gates Foundation Funds TesseraTx's Gene‑editing HIV Cure Research

1/🚨@TesseraTx has announced that it has received a grant from the Gates Foundation to fund an early-stage research which is aimed to develop a Gene Editing-based cure for HIV. This grant is build upon Tessera’s existing investment 🧵👇 from the Gates...

By Yair Einhorn
Bioventix SMA Adopted by Top IVD and Research Platforms
SocialMar 30, 2026

Bioventix SMA Adopted by Top IVD and Research Platforms

Positive update from Bioventix, confirming its position as a key player in the emerging Neurology & Alzheimer’s blood-testing market. “Amongst the RuO B-D pT217 assays being developed by the leading IVD companies (e.g. Roche, Siemens, Abbott, Beckman, Quidel-Ortho, Mindray etc.),...

By Leon Boros
Exposome Accelerates Brain Aging, Worsening Alzheimer’s Sleep Disturbances
SocialMar 30, 2026

Exposome Accelerates Brain Aging, Worsening Alzheimer’s Sleep Disturbances

Sleep disturbances and Alzheimer’s disease: a multiscale approach from exposome to neurobiology and precision medicine "a hypothetical integrative, stream-like model outlining how external and internal exposome factors accelerate brain aging, thereby exacerbating circadian dysregulation, orexin-mediated hyperexcitability, metabolic imbalance, and inflammaging." https://t.co/VJPZRqmM23

By David Barzilai, MD PhD
Stopping Alzheimer’s Drugs Speeds Decline, Raises Death Risk
SocialMar 29, 2026

Stopping Alzheimer’s Drugs Speeds Decline, Raises Death Risk

Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study https://t.co/YUcSc7w9HG

By David Barzilai, MD PhD
Modulating RNA Folding Boosts Drug Efficacy More than Binding
SocialMar 29, 2026

Modulating RNA Folding Boosts Drug Efficacy More than Binding

Small molecules that alter RNA structure, rather than simply binding to it, have a greater impact on RNA function, highlighting the importance of targeting RNA folding in drug development. molecularbiology

By Phys.org Threads
Network Pharmacology Reveals Natural Products' Neuroprotective Power
SocialMar 29, 2026

Network Pharmacology Reveals Natural Products' Neuroprotective Power

Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review https://t.co/LGgQeHQHwF https://t.co/OiCYu2OxZq

By David Barzilai, MD PhD
Rapamycin Lessens Age‑related Motor Decline, Varies by Sex
SocialMar 29, 2026

Rapamycin Lessens Age‑related Motor Decline, Varies by Sex

Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice 👉"Our results are consistent with the idea that rapamycin’s beneficial effects are mediated, at least in part, by reducing oxidative stress and ER stress-mediated apoptosis... https://t.co/b8EZwrDTXP

By David Barzilai, MD PhD
Natural SIRT1 Activators May Shield Early Alzheimer’s Microglia
SocialMar 29, 2026

Natural SIRT1 Activators May Shield Early Alzheimer’s Microglia

Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis? 🗣️"We will describe how SIRT1 can represent a key molecular link and an appealing target to harness microglial neuroprotective potential as...

By David Barzilai, MD PhD
MRK's Sotatercept Shows Inverse Dose Response in 6
SocialMar 29, 2026

MRK's Sotatercept Shows Inverse Dose Response in 6

$TENX $TECX 🤔 $MRK sotatercept high dose *missed* stat sig on 6MWT in P2 (and it wasn’t particularly close). The low dose hit stat sig (barely) and was the dose taken to P3. What to make of a...

By Adam May
GLP‑1 Drugs Now Help Psoriatic Arthritis Beyond Weight Loss
SocialMar 29, 2026

GLP‑1 Drugs Now Help Psoriatic Arthritis Beyond Weight Loss

The list of conditions for which GLP-1 drugs provide benefit independent of weight loss keeps growing. Add psoriatic arthritis #AAD26 @AADskin https://t.co/kJej6osXTS

By Eric Topol
SGLT2 Inhibitors Help HFrEF Mice via Off‑Target Effects
SocialMar 29, 2026

SGLT2 Inhibitors Help HFrEF Mice via Off‑Target Effects

SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice “The beneficial effects of SGLT2i treatment in gKO mice conclusively demonstrate that in a physiologically relevant preclinical model of HFrEF, SGLT2i can exert therapeutic benefits via off-target pharmacology.3...

By David Barzilai, MD PhD
Writing Genomes Opens Post‑Darwinian Era of ABI
SocialMar 29, 2026

Writing Genomes Opens Post‑Darwinian Era of ABI

Artificial Biological Intelligence (ABI) In a post-Darwinian era of being able to write genomes, the implications—both for good and harm—are profound. In conversation with @AdrianWoolfson on his new book On the Future of Species https://t.co/2OahzzxAAa

By Eric Topol
Published Errors Survive; Faulty Experiments Kill
SocialMar 29, 2026

Published Errors Survive; Faulty Experiments Kill

You can publish a paper with wrong data. You can't make a working drug with a wrong experiment. I wrote about HeLa contamination a few days ago. Then an Oxford researcher told me his story. https://t.co/77vvQQ8kq0

By Ming Tang
Rejuvenating Blood Stem Cells Boosts Whole‑Body Health
SocialMar 29, 2026

Rejuvenating Blood Stem Cells Boosts Whole‑Body Health

Hematopoietic (stem) cells—The elixir of life? "In this perspective article, we discuss the evidence that supports that rejuvenating or delaying aging of the blood system has a beneficial and systemic impact on human health..." @FEBS_Letters https://t.co/Y9sYcwXp1A @FEBSJournal

By David Barzilai, MD PhD
DNA Repair Drives Aging; OSK Reverses Epigenetic Decline
SocialMar 29, 2026

DNA Repair Drives Aging; OSK Reverses Epigenetic Decline

Loss of epigenetic information as a cause of mammalian aging “we find that the act of faithful DNA repair advances aging at physiological, cognitive, and molecular levels, including erosion of the epigenetic landscape, cellular exdifferentiation, senescence, and advancement of the DNA...

By David Barzilai, MD PhD
Epigenetic Dysregulation Fuels Aging, Offers Therapeutic Target
SocialMar 29, 2026

Epigenetic Dysregulation Fuels Aging, Offers Therapeutic Target

Systemic epigenetic dysregulation as a driver of ageing and a therapeutic target 👉 “By providing mechanistic clarity on how epigenetic dysregulation drives ageing phenotypes, we aim to enable rational design of therapeutics that target the epigenetic systems that fail during ageing,...

By David Barzilai, MD PhD
Intranasal 5-MeO-DMT Boosts Depression Relief with SSRIs
SocialMar 29, 2026

Intranasal 5-MeO-DMT Boosts Depression Relief with SSRIs

The results of this first phase 2a clinical trial of intranasal 5-MeO-DMT administered adjunctively to SSRIs demonstrated acceptable safety and tolerability with promising improvements in depressive symptoms. https://t.co/m15DkPP4qX

By Julie Holland
Senescent Immune Cells Guard Tissues, Delay Aging
SocialMar 29, 2026

Senescent Immune Cells Guard Tissues, Delay Aging

Senescent immune cells protect against damage, inflammation and disease 🤯 In mice, p16-expressing immune cells delay age-related organ deterioration and preserve tissue homeostasis. More evidence of the physiological roles of senescent cells? https://t.co/UtBKDF00P1

By João Pedro de Magalhães, PhD
Hib Vaccine Shields Against Meningitis, Pneumonia, Epiglottitis
SocialMar 29, 2026

Hib Vaccine Shields Against Meningitis, Pneumonia, Epiglottitis

The Hib vaccine protects against Haemophilus influenzae type b (Hib) bacteria, which can cause severe illnesses like meningitis, pneumonia, and epiglottitis. Th

By Dr. Leslie Treece, MD
FDA Greenlights Viagra: A Pivotal HealthTech Milestone
SocialMar 28, 2026

FDA Greenlights Viagra: A Pivotal HealthTech Milestone

#ThisDayInTechHistory. March 27, 1998. The FDA approved Viagra developed by Pfizer. (Untold Story) #HealthTech #JVGpost https://t.co/GJea9vd0v9

By James Gingerich
FDA Confirms Myocarditis Risk, Validating Parents' COVID Concerns
SocialMar 28, 2026

FDA Confirms Myocarditis Risk, Validating Parents' COVID Concerns

Great thread and one addition: Increased risk of myocarditis in young boys. The demonization of parents who asked, the denials by healthcare professionals and bureaucrats, and ultimately, the admission and subsequent FDA warning proving parents worst fears correct. It will take...

By Katherine Boyle
Microbial Phenolics Mediate Oats' Cholesterol‑lowering Power
SocialMar 28, 2026

Microbial Phenolics Mediate Oats' Cholesterol‑lowering Power

Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial "Here we show that microbial phenolic metabolites are driving factors for the cholesterol-lowering effect of oats.." https://t.co/Y6fmNYStmZ

By David Barzilai, MD PhD
PCSK9 Inhibitor Cuts Cardiovascular Events in Diabetics
SocialMar 28, 2026

PCSK9 Inhibitor Cuts Cardiovascular Events in Diabetics

In a randomized trial of a PCSK9 inhibitor [for LDL cholesterol lowering] vs placebo for patients with diabetes and no known heart disease, there was significant reduction of major cardiovascular events including deaths #ACC26 @JAMA_current https://t.co/mzuI79c4IN https://t.co/16Cpxf7IBx

By Eric Topol
Supercomputer Maps Spliceosome Dynamics, Advancing Gene‑Splicing Drug Design
SocialMar 28, 2026

Supercomputer Maps Spliceosome Dynamics, Advancing Gene‑Splicing Drug Design

Supercomputer simulations of a two-million-atom human cell model have mapped the dynamic motions of the spliceosome, offering detailed insights into gene splicing mechanisms and informing future drug development. computationalbiology

By Phys.org Threads
Intensive LDL < 55 Mg/dL Cuts Cardiovascular Events
SocialMar 28, 2026

Intensive LDL < 55 Mg/dL Cuts Cardiovascular Events

Validation of aggressive LDL lowering to reduce major adverse cardiovascular events, a randomized trial targeting LDL < 55 mg/dl. In participants with atherosclerotic cardiovascular disease (secondary prevention) @NEJM #ACC26 https://t.co/oLnkqhawOd

By Eric Topol
AI Meets Scalable Single-Cell Data, Transforming Medicine
SocialMar 28, 2026

AI Meets Scalable Single-Cell Data, Transforming Medicine

AI needs data. And biology is finally generating it at scale. I spoke with @10xGenomics CEO Serge Saxonov about the single-cell and spatial biology revolution — and why the convergence of AI + biological measurement could transform medicine. Read the full profile...

By John Cumbers
Combining Modest Therapies Unlocks Big Benefits, Reduces Waste
SocialMar 28, 2026

Combining Modest Therapies Unlocks Big Benefits, Reduces Waste

Adam, I used to think this way. Then gene therapy & IO worked. IL2 has consumed a lot of hope; but new variations make it hard to quit. Abeta worked. And synergy: combine modest drugs, unlock big benefits. Invest or...

By Peter Kolchinsky
Retatrutide's Sales Potential Tempered by Heart Risks
SocialMar 28, 2026

Retatrutide's Sales Potential Tempered by Heart Risks

I'm fairly sure retatrutide will be the largest peak-sales drug in history (inflation-adjusted). My lingering question is the resting HR elevation of ~5–7 bpm and a 4–14% arrhythmia rate (vs. 2–3% placebo) seen in Phase 2 data, plus insomnia reported...

By Bijan Salehizedah
New Atlas Maps All Human E3 Ligases, Unifying Research
SocialMar 28, 2026

New Atlas Maps All Human E3 Ligases, Unifying Research

A comprehensive atlas now defines all human E3 ligases, resolving decades of inconsistencies and providing a unified framework to advance research and therapeutic development for diseases linked to these essential enzymes. biotechnology

By Phys.org Threads
First Earnings Call Unveils AI‑Driven Aging Therapies
SocialMar 28, 2026

First Earnings Call Unveils AI‑Driven Aging Therapies

Our first ever earnings call coming up tomorrow - we are reporting our 2025 annual results. I will start the call with the 5 minute introduction to AI drug discovery and how we measure AI drug discovery productivity. In my...

By Alex Zhavoronkov, PhD
Spanish Team Sustains Human Uterus Alive for 24 Hours
SocialMar 28, 2026

Spanish Team Sustains Human Uterus Alive for 24 Hours

Scientists in Spain kept a donated human uterus alive for 24 hours using a machine that mimics the body's circulatory system, pumping modified blood through the organ.

By MIT Technology Review Threads
GLP‑1 Drugs Could Help Prevent Cancer, Study Shows
SocialMar 28, 2026

GLP‑1 Drugs Could Help Prevent Cancer, Study Shows

As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too. GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest...

By Robert Lufkin, MD
TTN's High Mutation Rate Reflects Size, Not Significance
SocialMar 28, 2026

TTN's High Mutation Rate Reflects Size, Not Significance

TTN shows up as one of the most mutated genes in almost every cancer exome. New bioinformaticians see it and think they found something. They didn't. It's a 364-exon gene encoding the largest human protein. It collects mutations like a lint...

By Ming Tang
Weekly Biotech Roundup: Top Posts Curated by BiopharmIQ
SocialMar 28, 2026

Weekly Biotech Roundup: Top Posts Curated by BiopharmIQ

Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...

By Yair Einhorn
Oral GLP‑1 Battle Heats up Amid FDA Uncertainty
SocialMar 28, 2026

Oral GLP‑1 Battle Heats up Amid FDA Uncertainty

Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...

By BowTiedBiotech
AI‑Designed Enzymes Signal SynBio’s Sugar‑Reduction Promise
SocialMar 28, 2026

AI‑Designed Enzymes Signal SynBio’s Sugar‑Reduction Promise

Can synbio solve sugar reduction? The @ArzedaCo + @ManeGroup partnership is a strong signal. AI-designed enzymes Cell-free manufacturing at scale Real products in market Excited to host Alexandre Zanghellini (@biopraxis) at #SynBioBeta2026. Visit the SynBioBeta website to read the full article: https://t.co/1S29MUqfWh

By John Cumbers
Β‑Hydroxybutyrate's Dual Impact on Colorectal Cancer
SocialMar 28, 2026

Β‑Hydroxybutyrate's Dual Impact on Colorectal Cancer

β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights https://t.co/pPCdm2AcFo https://t.co/mPtz1Xqiep

By David Barzilai, MD PhD
From Weight Loss to Longevity: Medicine Shifts Toward Prevention
SocialMar 28, 2026

From Weight Loss to Longevity: Medicine Shifts Toward Prevention

It’s interesting how quickly the conversation has shifted. Not long ago, people were hesitant about weight loss injections. Now the question is whether GLP-1s should be used… for longevity. That shift alone is worth paying attention to. Because it reflects something deeper — we’re...

By Marissa Dinar, MD
Earendil Labs Secures $787M to Accelerate AI Biologics
SocialMar 28, 2026

Earendil Labs Secures $787M to Accelerate AI Biologics

Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development Who is winning AI race again? https://t.co/ZW4S2zUGkS

By Paul Triolo